Xenomics, Inc. To Present at the Rodman & Renshaw 10th Annual Healthcare Conference
Xenomics, Inc. (XNOM.PK), a developer of non-invasive next-generation molecular diagnostics, announced today that it will present at the Rodman & Renshaw 10th Annual Healthcare Conference on Tuesday, November 11th in New York City. Dr. Samuil Umansky, Chief Scientific Officer of Xenomics, will provide an update on the Company’s lead programs and development strategy.
Rodman & Renshaw 10th Annual Healthcare Conference XNOM.PK Presentation: Tuesday, November 11th, 2008 4:05 PM EST/1:05 AM PST Holmes I, New York Palace Hotel, New York City
Xenomics is a molecular diagnostics company developing tests based on Transrenal nucleic acids (Tr-DNA and Tr-RNA) and safe, simple urine collection techniques. The Company believes its proprietary technology has a broad range of detection / monitoring / screening applications, including for prenatal conditions, infectious diseases, tissue transplantation, neurodegenerative disorders, various tumors, and can open significant new markets in the molecular diagnostics field. Currently, Xenomics is focusing on implementation of its urinary DNA-based test for high-risk Human Papilloma Virus (HPV) and development of other tests based on Tr-DNA and Tr-miRNA. Xenomics has a strong and broad IP portfolio of issued and pending patents covering different applications of the technology for molecular diagnostics.
More information is available on the Company’s website, www.xenomics.com.